Amarin Corp Plc - relatórios financeiros trimestrais (NASDAQ:AMRN)

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Trimestral Ano

Market Capitalization 295.4162 M
Employee 80
Founded 1989
CEO N/A
Website www.amarincorp.com
Headquarter United Kingdom
FIGI BBG000BPYG99
Industry Fabricantes de medicamentos - gerais

Receita total

Lucro líquido

Lucro básico por ação

Dívida total

Fluxo de caixa livre

Caixa e equivalentes de caixa

295.42 M Capitalização de mercado

Índice preço/lucro

-155.06

Índice preço/fluxo de caixa

27.11

Amarin Corporation plc - American Depositary Shares, each repre

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.

AMRN

Financials

Amarin Corporation plc - American Depositary Shares, each repre

Notícias

ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata

Amarin registra crescimento de receita no 1º tri de 2026 em meio a reestruturação

Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down

AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results

MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study

MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study

MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority Tag

BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up

Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up

Amarin apresentará dados de subgrupos do REDUCE-IT em congresso de cardiologia